The Mayo Clinic Cancer Center Pharmacy Shared Resource provides comprehensive pharmacy services in support of approximately 200 active cancer clinical trials across the 3 campuses of Mayo Rochester, Mayo Jacksonville, and Mayo Sccttsdale. The Pharmacy Shared Resource provides procurement, storage, and accountability of investigational agents. In addition, admixture of cytotoxic chemotherapy, growth factors, immunomodulatory agents, antiemetics, and supportive care medication is provided. The services of the Pharmacy Shared Resource are essential for protocol development, protocol initiation, and patient treatment on clinical trials throughout the Mayo Clinic Cancer Center. Special expertise with both investigational and commercially available cancer therapeutic agents resides in the Cancer Center Pharmacy Shared Resource, ensuring a uniformly high standard of safe and accurate treatment for all Mayo Clinic cancer patients. The utilization of the Pharmacy Shared Resource has increased over the past five years as noted by the number of patients treated on clinic trials. In 2002 the number of patients treated on clinical trials at the Mayo Clinic Cancer Center that utilized the Pharmacy Shared Resource was 1549, compared to 573 in 1997. This increase was due to the steady increase in patient accrual and the integration of Mayo Clinic Jacksonville and Mayo Clinic Scottsdale. The increased utilization of the Pharmacy Shared Resource is also demonstrated by an increased number of Mayo Clinic Cancer Center members utilizing the services of the Pharmacy core as well as the increased number of protocols in development. The main mission of the Pharmacy Shared Resource is to provide protocol development and review, investigational drug accountability, and chemotherapy admixture and dispensing services. The implementation of policies and procedures consistent with American Society of Health Systems Pharmacy guidelines and Joint Commission on Accreditation of Healthcare Organizations recommendations at each site ensures regulatory compliance and provides a uniform level of safe, high quality care to all Mayo Clinic Cancer Center patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015083-33
Application #
7414492
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2007-03-01
Budget End
2008-02-29
Support Year
33
Fiscal Year
2007
Total Cost
$252,602
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Kalli, Kimberly R; Block, Matthew S; Kasi, Pashtoon M et al. (2018) Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients. Clin Cancer Res 24:3014-3025
Wang, Sophia S; Carrington, Mary; Berndt, Sonja I et al. (2018) HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. Cancer Res 78:4086-4096
Norris, Robin E; Fox, Elizabeth; Reid, Joel M et al. (2018) Phase 1 trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A report from the Children's Oncology Group Phase 1 Pilot Consortium (ADVL1213). Pediatr Blood Cancer 65:e26944
Block, Matthew S; Vierkant, Robert A; Rambau, Peter F et al. (2018) MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. Mayo Clin Proc 93:307-320
Sharma, Ayush; Oishi, Naoki; Boddicker, Rebecca L et al. (2018) Recurrent STAT3-JAK2 fusions in indolent T-cell lymphoproliferative disorder of the gastrointestinal tract. Blood 131:2262-2266
Langlais, Blake T; Geyer, Holly; Scherber, Robyn et al. (2018) Quality of life and symptom burden among myeloproliferative neoplasm patients: do symptoms impact quality of life? Leuk Lymphoma :1-7
Yang, Ju Dong; Addissie, Benyam D; Mara, Kristin C et al. (2018) GALAD Score for Hepatocellular Carcinoma Detection in Comparison to Liver Ultrasound and Proposal of GALADUS Score. Cancer Epidemiol Biomarkers Prev :
Kurmi, Kiran; Hitosugi, Sadae; Yu, Jia et al. (2018) Tyrosine Phosphorylation of Mitochondrial Creatine Kinase 1 Enhances a Druggable Tumor Energy Shuttle Pathway. Cell Metab 28:833-847.e8
O'Mara, Tracy A; Glubb, Dylan M; Amant, Frederic et al. (2018) Identification of nine new susceptibility loci for endometrial cancer. Nat Commun 9:3166
Wallace, Sumer K; Halverson, Jessica W; Jankowski, Christopher J et al. (2018) Optimizing Blood Transfusion Practices Through Bundled Intervention Implementation in Patients With Gynecologic Cancer Undergoing Laparotomy. Obstet Gynecol 131:891-898

Showing the most recent 10 out of 1129 publications